Melissa Baylor, DO
Family Medicine · Dover, PANPI 1205851219
Payments from drug & device makers
Across 421 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$1K
- AbbVie$993
- Pfizer$480
- Johnson & Johnson$423
- Lilly USA, LLC$402
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,69099%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 85 | $1,271 |
| GSK | 74 | $1,130 |
| AbbVie(2 entities) | 51 | $993 |
| Pfizer | 39 | $480 |
| Johnson & Johnson | 26 | $423 |
| Lilly USA, LLC | 27 | $402 |
| AstraZeneca | 16 | $252 |
| Boehringer Ingelheim | 17 | $251 |
| Merck | 11 | $219 |
| Sanofi Pasteur Inc. | 7 | $143 |
| E.r. Squibb & Sons, L.L.C. | 8 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $138 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $99 |
| Novartis | 6 | $85 |
| Astellas Pharma US Inc | 3 | $83 |
| Amgen | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 4 | $61 |
| Amarin Pharma, Inc. | 4 | $60 |
| Bayer | 3 | $56 |
| Dexcom, Inc. | 3 | $54 |
| Abbott | 2 | $45 |
| Exact Sciences | 2 | $34 |
| Genentech USA, Inc. | 2 | $32 |
| Seqirus USA Inc | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| Viatris Specialty LLC | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Mannkind Corporation | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$6,740 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 378 | $330,875 |
| EliquisApixaban | 272 | $219,843 |
| OzempicSemaglutide | 111 | $149,648 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 166 | $129,010 |
| MounjaroTirzepatide | 66 | $70,315 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 117 | $36,378 |
| XareltoRivaroxaban | 19 | $28,969 |
| ProliaDenosumab | 16 | $27,547 |
| RybelsusSemaglutide | 16 | $27,060 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $26,047 |
| TradjentaLinagliptin | 16 | $20,287 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 91 | $20,039 |
| JanuviaSitagliptin Phosphate | 19 | $19,937 |
| FarxigaDapagliflozin Propanediol | 26 | $15,740 |
| EntrestoSacubitril/Valsartan | 17 | $13,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $251 | $351,161394 claims |
| PfizerEliquis | $480 | $219,843272 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix, Incruse Ellipta | $1,130 | $215,060426 claims |
| Novo NordiskOzempic, Rybelsus | $1,271 | $176,708127 claims |
| Lilly USA, LLCMounjaro | $402 | $70,31566 claims |
| Johnson & JohnsonXarelto | $423 | $28,96919 claims |
| AmgenProlia | $65 | $27,54716 claims |
| MerckJanuvia, Janumet Xr | $219 | $25,77131 claims |
| AstraZenecaFarxiga, Symbicort | $252 | $21,47242 claims |
| NovartisEntresto | $85 | $13,93717 claims |
| AbbVieLinzess, Synthroid | $993 | $12,15860 claims |
| Astellas Pharma US IncMyrbetriq | $83 | $7,43914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Dover
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.